The TORC1/2 inhibitor TAK-228 has also shown promise in treating NSCLC with NRF2 pathway alterations [79], and combination therapies with glutaminase inhibitors may help overcome resistance in LUSC [146]. This evidence concerns the gene NFE2L2 and non-small cell lung carcinoma.